Redhill Biopharma Ltd - Understand $rdhl stock

$RDHL Market Cap: $8.91 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$14.50M

TTM

Gross Margin

50.69%

TTM

Net Earnings

$71.83M

TTM

Current Assets

$15.70M

Q2 2024

Current Liabilities

$21.23M

Q2 2024

Current Ratio

73.96%

Q2 2024

Total Assets

$22.02M

Q2 2024

Total Liabilities

$21.96M

Q2 2024

Book Value

$61.00K

Q2 2024

Cash

$7.277M

Q2 2024

P/E

0.1240

Nov 15, 2024 EST

Free Cash Flow

-$42.01M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	$6.530M	$61.80M	$85.76M	$64.36M	$6.290M	$8.360M	$4.010M	$100.0K	$0.00	$7.010M	$10.00K	$20.00K
YoY Change	-89.43%	-27.94%	33.25%	923.21%	-24.76%	108.48%	3910.0%		-100.0%	70000.0%	-50.0%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	$6.530M	$61.80M	$85.76M	$64.36M	$6.290M	$8.360M	$4.010M	$100.0K	$0.00	$7.010M	$10.00K	$20.00K
Cost Of Revenue	$3.459M	$33.34M	$40.51M	$36.89M	$2.260M	$2.840M	$2.130M	$0.00	$0.00	$1.050M
Gross Profit	$3.071M	$28.46M	$45.25M	$27.47M	$4.030M	$5.520M	$1.880M	$100.0K	$0.00	$5.960M
Gross Profit Margin	47.03%	46.06%	52.77%	42.68%	64.07%	66.03%	46.88%	100.0%		85.02%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Selling, General & Admin	$30.98M	$28.59M	$87.99M	$74.66M	$29.81M	$19.99M	$20.04M	$5.400M	$4.130M	$4.010M	$2.680M	$2.600M
YoY Change	8.36%	-67.51%	17.85%	150.45%	49.12%	-0.25%	271.11%	30.75%	2.99%	49.63%	3.08%
% of Gross Profit	1008.63%	100.43%	194.44%	271.79%	739.7%	362.14%	1065.96%	5400.0%		67.28%
Research & Development	$3.528M	$7.279M	$29.50M	$16.49M	$17.42M	$24.86M	$32.97M	$25.24M	$17.77M	$12.70M	$8.100M	$6.460M
YoY Change	-51.53%	-75.32%	78.88%	-5.34%	-29.93%	-24.6%	30.63%	42.04%	39.92%	56.79%	25.39%
% of Gross Profit	114.88%	25.57%	65.19%	60.03%	432.26%	450.36%	1753.72%	25240.0%		213.09%
Depreciation & Amortization	$1.990M	$8.154M	$18.15M	$8.750M	$1.220M	$90.00K	$80.00K	$40.00K	$40.00K	$30.00K
YoY Change	-75.59%	-55.07%	107.42%	617.21%	1255.56%	12.5%	100.0%	0.0%	33.33%
% of Gross Profit	64.8%	28.65%	40.11%	31.85%	30.27%	1.63%	4.26%	40.0%		0.5%
Operating Expenses	-$9.561M	$35.87M	$117.5M	$91.15M	$47.23M	$44.85M	$53.85M	$30.64M	$22.01M	$16.61M	$10.78M	$9.060M
YoY Change	-126.66%	-69.47%	28.89%	92.99%	5.31%	-16.71%	75.75%	39.21%	32.51%	54.08%	18.98%
Operating Profit	$12.63M	-$7.402M	-$72.23M	-$63.68M	-$43.20M	-$39.33M	-$51.97M	-$30.54M	-$22.01M	-$10.65M
YoY Change	-270.66%	-89.75%	13.43%	47.41%	9.84%	-24.32%	70.17%	38.76%	106.67%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Interest Expense	-$7.477M	-$28.83M	-$16.61M	-$12.58M	$420.0K	$220.0K	$6.240M	$1.090M	$910.0K	-$60.00K	$60.00K	-$1.460M
YoY Change	-74.06%	73.55%	32.03%	-3095.24%	90.91%	-96.47%	472.48%	19.78%	-1616.67%	-200.0%	-104.11%
% of Operating Profit	-59.19%
Other Income/Expense, Net	-$1.824M	$0.00	$0.00	$90.00K	$470.0K	$300.0K	$190.0K	$80.00K			$80.00K	$180.0K
YoY Change			-100.0%	-80.85%	56.67%	57.89%	137.5%				-55.56%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Pretax Income	$23.92M	-$71.67M	-$97.74M	-$76.17M	-$42.30M	-$38.82M	-$45.54M	-$29.37M	-$21.09M	-$10.71M	-$10.63M	-$10.33M
YoY Change	-133.37%	-26.68%	28.32%	80.07%	8.96%	-14.76%	55.06%	39.26%	96.92%	0.75%	2.9%
Income Tax										$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	$23.92M	-$71.67M	-$97.74M	-$76.17M	-$42.30M	-$38.82M	-$45.54M	-$29.37M	-$21.09M	-$10.71M	-$10.63M	-$10.33M
YoY Change	-133.37%	-26.68%	28.32%	80.07%	8.96%	-14.76%	55.06%	39.26%	96.92%	0.75%	2.9%
Net Earnings / Revenue	366.25%	-115.97%	-113.98%	-118.35%	-672.5%	-464.35%	-1135.66%	-29370.0%		-152.78%	-106300.0%	-51650.0%
Basic Earnings Per Share
Diluted Earnings Per Share	$0.01	-$4.63	-$210.1K	-$209.1K	-$142.5K	-$167.9K	-$257.9K	-$228.5K	-$190.3K	-$123.7K	-$170.4K	-$196.4K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Cash & Short-Term Investments	$5.569M	$19.98M	$38.00M	$29.80M	$47.90M	$53.20M	$46.20M	$66.20M	$58.10M	$22.90M	$12.10M	$18.40M
YoY Change	-72.13%	-47.42%	27.53%	-37.79%	-9.96%	15.15%	-30.21%	13.94%	153.71%	89.26%	-34.24%
Cash & Equivalents
Short-Term Investments	$0.00	$6.660M	$9.114M	$15.50M	$41.40M	$45.40M	$37.90M	$12.40M	$52.10M	$18.40M	$4.400M	$11.70M
Other Short-Term Assets	$3.591M	$20.39M	$4.661M	$5.500M	$2.200M	$1.900M	$3.300M	$1.600M	$2.400M	$200.0K	$100.0K	$100.0K
YoY Change	-82.39%	337.4%	-15.25%	150.0%	15.79%	-42.42%	106.25%	-33.33%	1100.0%	100.0%	0.0%
Inventory	$4.389M	$11.01M	$14.81M	$6.500M	$1.900M	$800.0K	$700.0K	$0.00
Prepaid Expenses
Receivables	$2.591M	$34.52M	$31.68M	$28.70M	$1.200M	$1.000M	$1.500M	$100.0K		$2.900M	$400.0K	$100.0K
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00		$0.00	$0.00	$0.00
Total Short-Term Assets	$16.14M	$85.90M	$89.15M	$70.50M	$53.20M	$56.80M	$51.70M	$67.80M	$60.50M	$26.00M	$12.60M	$18.60M
YoY Change	-81.21%	-3.65%	26.46%	32.52%	-6.34%	9.86%	-23.75%	12.07%	132.69%	106.35%	-32.26%
Property, Plant & Equipment	$1.182M	$7.194M	$4.223M	$5.700M	$3.800M	$200.0K	$200.0K	$200.0K	$100.0K	$100.0K	$100.0K	$100.0K
YoY Change	-83.57%	70.35%	-25.91%	50.0%	1800.0%	0.0%	0.0%	100.0%	0.0%	0.0%	0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$147.0K	$150.0K	$16.17M	$16.20M	$200.0K	$100.0K	$200.0K	$100.0K	$100.0K	$100.0K	$100.0K	$100.0K
YoY Change	-2.0%	-99.07%	-0.19%	8000.0%	100.0%	-50.0%	100.0%	0.0%	0.0%	0.0%	0.0%
Total Long-Term Assets	$6.907M	$72.97M	$92.04M	$109.7M	$20.90M	$5.600M	$5.600M	$6.400M	$6.300M	$2.900M	$1.700M	$1.500M
YoY Change	-90.53%	-20.72%	-16.1%	424.88%	273.21%	0.0%	-12.5%	1.59%	117.24%	70.59%	13.33%
Total Assets	$23.05M	$158.9M	$181.2M	$180.2M	$74.10M	$62.40M	$57.30M	$74.20M	$66.80M	$28.90M	$14.30M	$20.10M
YoY Change
Accounts Payable	$3.278M	$15.39M	$28.25M	$29.10M	$4.200M	$3.300M	$5.800M	$2.100M	$2.200M	$100.0K	$900.0K	$400.0K
YoY Change	-78.7%	-45.52%	-2.94%	592.86%	27.27%	-43.1%	176.19%	-4.55%	2100.0%	-88.89%	125.0%
Accrued Expenses	$4.592M	$17.95M	$20.90M	$24.10M	$5.600M	$7.100M	$6.000M	$3.300M	$3.300M	$1.600M	$1.500M	$700.0K
YoY Change	-74.42%	-14.1%	-13.29%	330.36%	-21.13%	18.33%	81.82%	0.0%	106.25%	6.67%	114.29%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$718.0K	$116.2M	$1.618M	$1.700M	$800.0K
YoY Change	-99.38%	7084.67%	-4.82%	112.5%
Total Short-Term Liabilities	$19.24M	$197.5M	$81.47M	$73.20M	$10.60M	$10.40M	$11.80M	$5.400M	$5.500M	$1.700M	$2.400M	$1.100M
YoY Change	-90.25%	142.36%	11.3%	590.57%	1.92%	-11.86%	118.52%	-1.82%	223.53%	-29.17%	118.18%
Long-Term Debt	$455.0K	$6.443M	$86.19M	$85.20M	$3.000M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-92.94%	-92.53%	1.17%	2740.0%
Other Long-Term Liabilities	$1.281M	$3.373M	$4.649M	$7.900M	$500.0K	$800.0K	$400.0K	$6.200M	$1.200M	$2.100M	$0.00	$0.00
YoY Change	-62.02%	-27.45%	-41.15%	1480.0%	-37.5%	100.0%	-93.55%	416.67%	-42.86%
Total Long-Term Liabilities	$1.736M	$9.816M	$90.84M	$93.10M	$3.500M	$800.0K	$400.0K	$6.200M	$1.200M	$2.100M	$0.00	$0.00
YoY Change	-82.31%	-89.19%	-2.42%	2560.0%	337.5%	100.0%	-93.55%	416.67%	-42.86%
Total Liabilities	$20.98M	$207.3M	$172.3M	$166.4M	$14.10M	$11.20M	$12.30M	$11.50M	$6.800M	$3.800M	$2.400M	$1.100M
YoY Change	-89.88%	20.29%	3.55%	1080.14%	25.89%	-8.94%	6.96%	69.12%	78.95%	58.33%	118.18%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $8.91 Million

About Redhill Biopharma Ltd

RedHill Biopharma Ltd. develops medicines for gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.

Industry: Pharmaceutical Preparations Peers: Scinai Immunotherapeutics Ltd Mediwound Ltd PainReform Ltd PolyPid Ltd